SCHEMBL695236

SCHEMBL695236

Cc1c[c]cc2cc(-c3ccc(F)cc3)[nH]c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.40
NPY5R Q15761 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
GCGR P47871 2/20 0.37
MAPK14 Q16539 2/20 0.37
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP1B1 Q16678 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694712 0.84 CCNB2 (0.38) CYP1A1NPY5RADORA2AADORA1GCGR
SCHEMBL694774 0.78 MGAM (0.45) CYP1A1NPY5RADORA2AADORA1GCGR
SCHEMBL695386 0.72 CYP1A1 (0.45) CYP1A1ADORA2AADORA1GCGRMAPK14
SCHEMBL24098965 0.71 NPY5R (0.42) CYP1A1NPY5RADORA2AADORA1GCGR
SCHEMBL694886 0.70 CYP1A1 (0.44) CYP1A1NPY5RADORA2AADORA1GCGR
SCHEMBL22118349 0.69 CYP1A1 (0.45) CYP1A1NPY5RADORA2AADORA1GCGR
SCHEMBL9784280 0.68 ACHE (0.40) GCGRMAPK14KDM4ETNKS2MGAM
SCHEMBL16720322 0.68 CTSV (0.43) CYP1A1ADORA2AADORA1GCGRMAPK14
SCHEMBL4568270 0.68 CYP1A1 (0.52) CYP1A1ADORA2AADORA1GCGRMAPK14
SCHEMBL22118352 0.67 CYP1A1 (0.43) CYP1A1NPY5RADORA2AADORA1GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197450-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-08-02 EP disclosed
WO-2016046130-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-03-31 WO disclosed
EP-2421825-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP disclosed
WO-2010124108-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed